astrazeneca glp 1 AstraZeneca’s experimental obesity pill helped patients lose up to 11.8% of their body weight in a mid-stage trial, as competition intensifies in the rapidly growing market for oral weight-loss drugs. Peptide-oligourea hybrids analogue of GLP-1

The researchers caution that while semaglutide remains a valuable tool for diabetes and obesity management, its use in patients with GLP-1 receptor-positive tumors should be carefully evaluated

Vascular dysfunction serves as the primary underlying cause of cardiovascular illness occurrence in patients experiencing anomalous glucose metabolism

DURATION-1: exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks

Retatrutide, a triple GIP/GLP-1/glucagon receptor agonist, normalized liver fat in 90 percent of patients after 48 weeks

Mind Clarity : It cuts down oxidative stress, sharpening your focus and lifting that mental haze